Targeted Liposomes Drug Delivery Market Application, Growth Factors, Development and Forecast 2027

Research Reports

Apr 14, 2022

Targeted Liposomes Drug Delivery Market is expected to reach a value of USD 2,975.17 Million, at a CAGR of 10.28% during the assessment period.

The market for liposome drug delivery is being pushed by rising chronic illness prevalence, rising need for non-invasive drug delivery options, and rising pharmaceutical R&D expenditures.

In 2019, the liposomal doxorubicin sector held more than 36.22 percent of the market share; in terms of technology, stealth liposome technology owned the greatest market proportion in 2019; and in terms of application, the cancer treatment segment held the highest share of the market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8756

Targeted Liposomes Drug Delivery Market

Market Segmentation

By Type

Doxorubicin in Pegylated Liposomes: Liposomal doxorubicin is doxorubicin enclosed in tiny spheres known as pegylated liposomes. These spheres prolong the time doxorubicin spends in the bloodstream, allowing more medicine to reach cancer cells. This kind is often used to treat cancers like ovarian cancer, breast cancer, and multiple myeloma. The increasing incidence rate of malignancies is likely to boost the expansion of this market.

Liposomal Paclitaxel: Liposomal Paclitaxel causes apoptosis by inactivating the B-cell Leukemia 2 (Bcl-2) protein, an apoptosis inhibitor. This causes this segment to be elevated. Paclitaxel liposome formulation may improve the delivery of larger paclitaxel dosages to target tissues while reducing systemic toxicity. The high efficacy rate of this type drives up the demand for its utilization.

Liposomal Amphotericin B: It is a drug used to deal with various fungal and parasite illnesses. This category is growing due to the growing number of patients with fungal infections.

Folate targeting liposomes and others are included in others.

By Application

Fungal Infection Therapy: Fungal infections are treated using liposomal medications such as Amphoteric and AmBisome. The category is expected to develop in the future as the frequency of fungal infections rises.

Cancer Therapy (Tumor Therapy): A targeted liposome drug delivery method is used in cancer therapy. Doxil and Myocet, amongst many others, are doxorubicin-based injectable polymeric nanoparticle medication formulations for cancer therapy.

Others: Liposomes seem to be a popular carrier method for vaccines and gene therapies, among other applications.

Regional Classification

Americas: Because significant participants in the targeted liposomes drug delivery sector are increasingly pursuing strategic initiatives like mergers, partnerships, acquisitions, as well as joint ventures, the Americas is estimated to be the leading regional market.

Middle East & Africa: This is the smallest market due to a lack of healthcare infrastructure and the availability of novel solutions.

Asia-Pacific: In the focused liposomes drug delivery market, the Asia-Pacific area is expected to develop fastest.

Europe: The European region has the second-largest share, owing to increased legislative support and increased market awareness established by important companies.

Industry News

Chronic disease prevalence has prompted increased research and development (R & R&D) in liposomal drug delivery systems during the last few decades. The procedure of giving a pharmaceutical ingredient to humans to achieve a therapeutic effect is known as drug delivery. Liposomal drug delivery has several advantages, including better therapeutic effectiveness, pharmacokinetics and pharmacodynamics, and reduced toxicity, making it excellent for patients with various chronic illnesses. According to the Centers for Disease Control and Prevention (CDC), about 6 out of 10 Americans have had at least one chronic illness, and 4 out of 10 had two or more chronic illnesses in 2019.

Market Key Players:

Catalent (US),Pacira Pharmaceuticals, Inc. (US),Baxter (US),Lonza (Switzerland),Evonik (Germany),Merck KGaA (Germany),Fareva (France),Vetter (Germany), Polymun Scientific Immunbiologische Forschung GmbH (Austria),Recipharm AB (Sweden), Dalton Pharma Services (Canada) are some of the key players in the market.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/targeted-liposomes-drug-delivery-market-8756  

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Related Reports:

Cancer Biomarker Market

Autoimmune Disease Treatment Market

U.S. Dietary supplements Market

Cervical Cancer Treatment Market

Delirium Market

Tags: Targeted Liposomes Drug Delivery Market, Targeted Liposomes Drug Delivery Market Trends, Targeted Liposomes Drug Delivery Market Industry, Targeted Liposomes Drug Delivery Market News, Targeted Liposomes Drug Delivery Market Research See Campaign: https://www.marketresearchfuture.com/reports/targeted-liposomes-drug-delivery-market-8756

Contact Information:

Market Research Future (part of Wantstats Research and Media Private Limited), 99 Hudson Street,5Th Floor, New York, New York 10013, United States of America +1 646 845 9312 Email: sales@marketresearchfuture.com

Tags:
PR-Wirein, Wire, Research Newswire, English

YOU MAY ALSO LIKE

Aquarium Market Set for Robust Growth: 16,216.10…

Targeted Liposomes Drug Delivery Market is expected to reach a value of USD 2,975.17 Million, at a CAGR of 10.28% during the assessment period. The…

read more

Wafer Biscuit Market to Touch USD 52.7…

Targeted Liposomes Drug Delivery Market is expected to reach a value of USD 2,975.17 Million, at a CAGR of 10.28% during the assessment period. The…

read more

Vitamin C Ingredients Market expected to reach…

Targeted Liposomes Drug Delivery Market is expected to reach a value of USD 2,975.17 Million, at a CAGR of 10.28% during the assessment period. The…

read more